High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda

• Published in: PloS one 2013-05, Vol.8 (5), p.e63303-e63303
• Main Authors: Rusine, John, Ondoa, Pascale, Asiimwe-Kateera, Brenda, Boer, Kimberly R, Uwimana, Jean Marie, Mukabayire, Odette, Zaaijer, Hans, Mugabekazi, Julie, Reiss, Peter, van de Wijgert, Janneke H
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adult; Adults; AIDS; Analysis; Antibodies; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; Antiretroviral Therapy, Highly Active - methods; Biology; Care and treatment; CD4 antigen; CD4 Antigens - immunology; Cohort Studies; Coinfection - epidemiology; Coinfection - immunology; Coinfection - virology; Disease Progression; Female; Hepacivirus - immunology; Hepatitis; Hepatitis B; Hepatitis B - epidemiology; Hepatitis B - immunology; Hepatitis B - virology; Hepatitis B surface antigen; Hepatitis B virus - immunology; Hepatitis C; Hepatitis C - epidemiology; Hepatitis C - immunology; Hepatitis C - virology; Hepatitis C Antibodies - immunology; Hepatitis C virus; Highly active antiretroviral therapy; HIV; HIV infections; HIV Infections - complications; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - virology; Human immunodeficiency virus; Humans; Incidence; Infection; Infections; Lamivudine; Male; Medical research; Medicine; Patients; Prevalence; Prospective Studies; Regression models; Ribonucleic acid; RNA; Rwanda - epidemiology; Seroepidemiologic Studies; Serology; Vaccination; Viral Load - immunology; Viruses; Womens health
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0063303

Data on prevalence and incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in Rwanda are scarce. HBV status was assessed at baseline and Month 12, and anti-HCV antibodies at baseline, in a prospective cohort study of HIV-infected patients in Kigali, Rwanda: 104 men and 114 women initiating antiretroviral therapy (ART) at baseline, and 200 women not yet eligible for ART. Baseline prevalence of active HBV infection (HBsAg positive), past or occult HBV infection (anti-HBc positive and HBsAg negative) and anti-HCV was 5.2%, 42.9%, and 5.7%, respectively. The active HBV incidence rate was 4.2/1,000 person years (PY). In a multivariable logistic regression model using baseline data, participants with WHO stage 3 or 4 HIV disease were 4.19 times (95% CI 1.21-14.47) more likely to have active HBV infection, and older patients were more likely to have evidence of past exposure to HBV (aRR 1.03 per year; 95%CI 1.01-1.06). Older age was also positively associated with having anti-HCV antibodies (aOR 1.09; 95%CI 1.04-1.14) while having a higher baseline HIV viral load was negatively associated with HCV (aOR 0.60; 95% CI 0.40-0.98). The median CD4 increase during the first 12 months of ART was lower for those with active HBV infection or anti-HCV at baseline. Almost all participants (88%) with active HBV infection who were on ART were receiving lamivudine monotherapy for HBV. HBV and HCV are common in HIV-infected patients in Rwanda. Regular HBsAg screening is needed to ensure that HIV-HBV co-infected patients receive an HBV-active ART regimen, and the prevalence of occult HBV infection should be determined. Improved access to HBV vaccination is recommended. Active HCV prevalence and incidence should be investigated further to determine whether HCV RNA PCR testing should be introduced in Rwanda.